Clinical Trial Update: Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 study sponsored by the National Cancer Institute evaluating arsenic trioxide in pediatric patients with refractory leukemia or lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED